{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:20:38Z","timestamp":1787509238979,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010878","name":"AbbVie Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010878","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Genmab A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary results from the EPCORE NHL-3 trial (NCT04542824) showed deep, durable responses in Japanese patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) treated with single-agent epcoritamab, a subcutaneous CD3xCD20 bispecific antibody. Here, we report 3-year follow-up of safety and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Japanese patients with R\/R CD20\n                      <jats:sup>+<\/jats:sup>\n                      DLBCL and\u00a0\u2009\u2265\u20092 prior systemic therapies received epcoritamab (0.16\/0.8-mg step-up doses, then 48-mg full doses) according to the approved label. The primary endpoint was overall response rate per independent review committee.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of July 12, 2024, 36 patients received epcoritamab (median follow-up, 36.7\u00a0months). Overall\/complete response rates were 56%\/47%. Median duration of response was 15.2\u00a0months. Median duration of complete response was not reached; an estimated 53% of complete responders remained in complete response at 3\u00a0years. Median progression-free\/overall survival (PFS\/OS) were 4.1\/14.9\u00a0months overall; neither was reached among complete responders. Three-year PFS\/OS estimates were 25%\/39% overall and 53%\/71% in complete responders. Among 30 evaluable patients, 17 (57%) became minimal residual disease (MRD) negative, which was associated with longer PFS (cycle 3\u00a0day 1 landmark analysis). The most common treatment-emergent adverse events (TEAEs) were cytokine release syndrome (83%), injection-site reaction (69%), and neutropenia (39%), consistent with previous reports. No fatal TEAEs occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With\u2009\u00a0&gt;\u20093\u00a0years of follow-up, epcoritamab treatment has consistently shown durable responses and high rates of MRD negativity in Japanese patients with R\/R DLBCL. Safety was similar to previous reports. These long-term remissions reaffirm encouraging outcomes with epcoritamab for this challenging-to-treat population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-025-02788-0","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T03:18:17Z","timestamp":1748402297000},"page":"1631-1640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kumode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8955","authenticated-orcid":false,"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Jafarinasabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"D\u2019Angelo M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Favaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"4","key":"2788_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12185-018-2430-6","volume":"107","author":"H Miyoshi","year":"2018","unstructured":"Miyoshi H, Ohshima K (2018) Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia\/lymphoma in Japan. Int J Hematol 107(4):420\u2013427. https:\/\/doi.org\/10.1007\/s12185-018-2430-6","journal-title":"Int J Hematol"},{"issue":"11","key":"2788_CR2","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1002\/cam4.1805","volume":"7","author":"R Muto","year":"2018","unstructured":"Muto R, Miyoshi H, Sato K et al (2018) Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med 7(11):5843\u20135858. https:\/\/doi.org\/10.1002\/cam4.1805","journal-title":"Cancer Med."},{"issue":"10","key":"2788_CR3","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/jco.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32(10):1066\u20131073. https:\/\/doi.org\/10.1200\/jco.2013.51.5866","journal-title":"J Clin Oncol"},{"issue":"7","key":"2788_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/jco.2016.70.0765","volume":"35","author":"LH Jakobsen","year":"2017","unstructured":"Jakobsen LH, B\u00f8gsted M, Brown PN et al (2017) Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol 35(7):778\u2013784. https:\/\/doi.org\/10.1200\/jco.2016.70.0765","journal-title":"J Clin Oncol"},{"issue":"16","key":"2788_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"issue":"1","key":"2788_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N et al (2016) Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant 51(1):51\u201357. https:\/\/doi.org\/10.1038\/bmt.2015.213","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2788_CR7","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1111\/cas.14937","volume":"112","author":"Y Terui","year":"2021","unstructured":"Terui Y, Rai S, Izutsu K et al (2021) A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci 112(7):2845\u20132854. https:\/\/doi.org\/10.1111\/cas.14937","journal-title":"Cancer Sci"},{"issue":"10","key":"2788_CR8","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","volume":"29","author":"R Houot","year":"2023","unstructured":"Houot R, Bachy E, Cartron G et al (2023) Axicabtagene ciloleucel as second-line therapy in large B-cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med 29(10):2593\u20132601. https:\/\/doi.org\/10.1038\/s41591-023-02572-5","journal-title":"Nat Med"},{"issue":"1","key":"2788_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"14","key":"2788_CR10","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason JE et al (2023) Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood 141(14):1675\u20131684. https:\/\/doi.org\/10.1182\/blood.2022018730","journal-title":"Blood"},{"issue":"6","key":"2788_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/cas.13239","volume":"108","author":"S Makita","year":"2017","unstructured":"Makita S, Yoshimura K, Tobinai K (2017) Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 108(6):1109\u20131118. https:\/\/doi.org\/10.1111\/cas.13239","journal-title":"Cancer Sci"},{"issue":"8","key":"2788_CR12","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jval.2022.02.007","volume":"25","author":"AJ Chen","year":"2022","unstructured":"Chen AJ, Zhang J, Agarwal A et al (2022) Value of reducing wait times for chimeric antigen receptor T-cell treatment: evidence from randomized controlled trial data on tisagenlecleucel for diffuse large B-cell lymphoma. Value Health 25(8):1344\u20131351. https:\/\/doi.org\/10.1016\/j.jval.2022.02.007","journal-title":"Value Health"},{"issue":"12","key":"2788_CR13","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/jco.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol 41(12):2238\u20132247. https:\/\/doi.org\/10.1200\/jco.22.01725","journal-title":"J Clin Oncol"},{"issue":"12","key":"2788_CR14","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H et al (2024) Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38(12):2653\u20132662. https:\/\/doi.org\/10.1038\/s41375-024-02410-8","journal-title":"Leukemia"},{"key":"2788_CR15","doi-asserted-by":"crossref","unstructured":"Dickinson M, Carlo-Stella C, Morschhauser F et al (2024) Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal Phase II study [oral presentation]. Annual Meeting and Exposition of the American Society of Hematology; December 7\u201310, 2024; San Diego, CA.","DOI":"10.1182\/blood-2024-194333"},{"issue":"3","key":"2788_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim WS, Kim TM, Cho SG et al (2025) Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer 6(3):528\u2013539. https:\/\/doi.org\/10.1038\/s43018-025-00921-6","journal-title":"Nat Cancer"},{"key":"2788_CR17","unstructured":"Epkinly [Japan package insert]. Minato-Ku, Tokyo, Japan: AbbVie GK, Genmab K.K.; 2025."},{"key":"2788_CR18","unstructured":"Epkinly [package insert]. Plainsboro, NJ, USA: Genmab US, Inc.; 2024."},{"key":"2788_CR19","unstructured":"Tepkinly [summary of product characteristics]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG; 2024."},{"issue":"12","key":"2788_CR20","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1111\/cas.15996","volume":"114","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Kumode T, Yuda J et al (2023) Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci 114(12):4643\u20134653. https:\/\/doi.org\/10.1111\/cas.15996","journal-title":"Cancer Sci"},{"issue":"1","key":"2788_CR21","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2024-198714","volume":"144","author":"JM Vose","year":"2024","unstructured":"Vose JM, Cheah CY, Clausen MR et al (2024) 3-year update from the EPCORE NHL-1 trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. Blood 144(suppl 1):4480\u20134482.","journal-title":"Blood."},{"issue":"27","key":"2788_CR22","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"17","key":"2788_CR23","doi-asserted-by":"publisher","first-page":"9736","DOI":"10.3390\/ijms25179736","volume":"25","author":"E Bayly-McCredie","year":"2024","unstructured":"Bayly-McCredie E, Treisman M, Fiorenza S (2024) Safety and efficacy of bispecific antibodies in adults with large B-cell lymphomas: a systematic review of clinical trial data. Int J Mol Sci 25(17):9736. https:\/\/doi.org\/10.3390\/ijms25179736","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2788_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","volume":"30","author":"LE Budde","year":"2024","unstructured":"Budde LE, Olszewski AJ, Assouline S et al (2024) Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B-cell lymphoma: a phase 1b\/2 trial. Nat Med 30(1):229\u2013239. https:\/\/doi.org\/10.1038\/s41591-023-02726-5","journal-title":"Nat Med"},{"issue":"1","key":"2788_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"26","key":"2788_CR26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"24","key":"2788_CR27","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1002\/cam4.4820","volume":"11","author":"S Makita","year":"2022","unstructured":"Makita S, Yamamoto G, Maruyama D et al (2022) Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer Med 11(24):4889\u20134899. https:\/\/doi.org\/10.1002\/cam4.4820","journal-title":"Cancer Med"},{"issue":"1","key":"2788_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10147-021-02033-4","volume":"27","author":"K Kato","year":"2022","unstructured":"Kato K, Makita S, Goto H et al (2022) Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma. Int J Clin Oncol 27(1):213\u2013223. https:\/\/doi.org\/10.1007\/s10147-021-02033-4","journal-title":"Int J Clin Oncol"},{"key":"2788_CR29","doi-asserted-by":"publisher","first-page":"e102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B et al (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. eBioMedicine 52:102625. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","journal-title":"BioMedicine."}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02788-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02788-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:00:11Z","timestamp":1757174411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02788-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02788-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koji Izutsu reports honoraria\/fees from Janssen and Ono Pharmaceutical and research funding from AbbVie, Incyte, Bristol Myers Squibb, Novartis, Janssen, Yakult, Daiichi Sankyo, Chugai, BeiGene, and Genmab. Takahiro Kumode reports honoraria\/fees from Janssen, AstraZeneca, AbbVie, Genmab, BeiGene, and Ono Pharmaceutical. Junichiro Yuda has nothing to disclose. Hirokazu Nagai reports honoraria\/fees from Chugai, Janssen, Meiji Seika, and Ono Pharmaceutical and scholarship endowments\/academic research funding from Chugai, AstraZeneca, Janssen, Genmab, AbbVie, Daiichi Sankyo, BeiGene, Eli Lilly, and Kyowa Kirin. Yuko Mishima reports honoraria\/fees from Chugai and Roche and scholarship endowments\/academic research funding from Takeda, Eisai, and Bristol Myers Squibb. Youko Suehiro reports research funding from Chugai, Genmab, Incyte, Amgen, Otsuka, AbbVie, Kyowa Kirin, and All Japan Pharma. Kazuhito Yamamoto reports honoraria\/fees from AbbVie, Chugai, Eisai, HUYA, IQVIA, Janssen, Meiji Seika, Micron, Daiichi Sankyo, and Takeda and research funding from Genmab, IQVIA, and Yakult. Tomoaki Fujisaki has nothing to disclose. Kenji Ishitsuka has nothing to disclose. Kenichi Ishizawa reports honoraria\/fees from Bristol Myers Squibb, Chugai, Eisai, and Novartis and research funding from Pfizer, SymBio, AbbVie, Chugai, and Zenyaku. Takayuki Ikezoe reports honoraria\/fees from Chugai, Asahi Kasei, and Nippon Shinyaku; research funding from Asahi Kasei; and scholarship endowments\/academic research funding from Asahi Kasei, Novartis, Alexion, Janssen, Dainippon Sumitomo, Nippon Shinyaku, Takeda, AbbVie, Incyte, Otsuka, and GSK. Momoko Nishikori reports honoraria\/fees from Chugai and Janssen and research funding from SymBio. Daigo Akahane has nothing to disclose. Jiro Fujita has nothing to disclose. Pegah Jafarinasabian reports current employment at AbbVie. David Soong reports current employment and is a stockholder at Genmab. Barbara D\u2019Angelo M\u00e5nsson reports current employment and is a stockholder at Genmab. Ami Takahashi reports current employment and is a stockholder at Genmab. Elena Favaro reports current employment and is a stockholder at Genmab. Noriko Fukuhara reports honoraria\/fees from Bristol Myers Squibb, Chugai, HUYA, and SymBio and research funding from AbbVie, Bayer, Bristol Myers Squibb, Chordia, Chugai, Genmab, Incyte, Kyowa Kirin, Loxo Oncology, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}